Reliability and validity of D‑dimer monitoring for pulmonary thromboembolism in patients with unresectable, advanced or recurrent colorectal cancer treated with bevacizumab

Kanehira,Dan; Kusakabe,Masashi; Shimizu,Sachio; Shimizu,Junichi; Irikuchi,Jinshi; Hirai,Akihiro; Oki,Ryosuke; Kato,Toshiaki; Yamasaki,Masao; Uchino,Keita

doi:10.3892/mco.2021.2327

August-2021 Volume 15 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2021 Volume 15 Issue 2

Full Size Image

Article

Reliability and validity of D‑dimer monitoring for pulmonary thromboembolism in patients with unresectable, advanced or recurrent colorectal cancer treated with bevacizumab

Authors:
- Dan Kanehira
- Masashi Kusakabe
- Sachio Shimizu
- Junichi Shimizu
- Jinshi Irikuchi
- Akihiro Hirai
- Ryosuke Oki
- Toshiaki Kato
- Masao Yamasaki
- Keita Uchino
View Affiliations / Copyright

Affiliations: Department of Chemotherapy, NTT Medical Center Tokyo, Tokyo 141‑0022, Japan, Department of Radiology, NTT Medical Center Tokyo, Tokyo 141‑0022, Japan, Department of Pharmacy, NTT Medical Center Tokyo, Tokyo 141‑0022, Japan, Department of Medical Oncology, NTT Medical Center Tokyo, Tokyo 141‑0022, Japan, Department of Cardiology, NTT Medical Center Tokyo, Tokyo 141‑0022, Japan
Article Number: 165
|
Published online on: June 17, 2021

https://doi.org/10.3892/mco.2021.2327
Expand metrics +

Abstract

Pulmonary thromboembolism (PTE) is one of the leading causes of death among cancer outpatients. The aim of the present study was to investigate the reliability and validity of D‑dimer monitoring for PTE in patients with unresectable, advanced or recurrent colorectal cancer treated with bevacizumab. A total of 25 patients with advanced colorectal cancer who received bevacizumab combination chemotherapy as primary treatment were retrospectively reviewed. The selection criteria included that D‑dimer tests were performed repetitively, and that chest and abdominal contrast‑enhanced CT scans were completed. The D‑dimer levels and the presence or absence of PTE on CT images were retrospectively examined. Four cases (16%) were detected as having asymptomatic PTE. The D‑dimer values at the onset of PTE were 14.2, 4.6, 1.1 and 0.9 µg/ml. The negative predictive value was 90.5% when 3.0 µg/ml was set as the D‑dimer level cutoff value. The incidence of PTE, including asymptomatic PTE, in the present study was higher compared with that reported in previous studies on various types of cancer, of various stages and treated with different chemotherapy regimens. In patients with bevacizumab‑treated unresectable, advanced or recurrent colorectal cancer, the D‑dimer test was found to be less useful for exclusion diagnosis; however, along with chest CT, it may be useful in the detection and diagnosis of PTE. However, the determination of the optimal reference values and appropriate measurement timing of D‑dimer testing requires further study.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16:1306–1315. 2015.PubMed/NCBI View Article : Google Scholar
3	Khorana AA: Venous thromboembolism and prognosis in cancer. Thromb Res. 125:490–493. 2010.PubMed/NCBI View Article : Google Scholar
4	Fernandes CJ, Morinaga LTK, Alves JL, Castro MA, Calderaro D, Jardim CVP and Souza R: Cancer-associated thrombosis: The when, how and why. Eur Respir Rev. 28(180119)2019.PubMed/NCBI View Article : Google Scholar
5	Nalluri SR, Chu D, Keresztes R, Zhu X and Wu S: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA. 300:2277–2285. 2008.PubMed/NCBI View Article : Google Scholar
6	Alahmari AK, Almalki ZS, Alahmari AK and Guo JJ: Thromboembolic events associated with bevacizumab plus chemotherapy for patients with colorectal cancer: A meta-analysis of randomized controlled trials. Am Heal Drug Benefits. 9:221–231. 2016.PubMed/NCBI
7	Crawford F, Andras A, Welch K, Sheares K, Keeling D and Chappell FM: D-dimer test for excluding the diagnosis of pulmonary embolism. Cochrane Database Syst Rev. 2016(CD010864)2016.PubMed/NCBI View Article : Google Scholar
8	Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, Yano T, Tahara M, Kaneko K, Doi T, et al: Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. Jpn J Clin Oncol. 40:933–937. 2010.PubMed/NCBI View Article : Google Scholar
9	Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, et al: Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 25:1–42. 2020.PubMed/NCBI View Article : Google Scholar
10	van Es N, Bleker SM and Di Nisio M: Cancer-associated unsuspected pulmonary embolism. Thromb Res. 133 (Suppl 1):S172–S178. 2014.PubMed/NCBI View Article : Google Scholar
11	Khorana AA, Kuderer NM, Culakova E, Lyman GH and Francis CW: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 111:4902–4907. 2008.PubMed/NCBI View Article : Google Scholar
12	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
13	Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 38:496–520. 2020.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Reliability and validity of D‑dimer monitoring for pulmonary thromboembolism in patients with unresectable, advanced or recurrent colorectal cancer treated with bevacizumab

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles